

EQA round: KD3/24 - Glycated Haemoglobin

Deadline: 26.7.2024

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

RoM = robust average

AV = assigned value

D_{max} = acceptable difference

SD = standard deviation

CVP = consensus of all participants

LL = lower limit

CV = coefficient of variation

U_{AV} = expanded uncertainty of the assigned value (k = 2)

UL = upper limit

N_{tot} = total number of the resultsN_{eva} = number of the results assessedN_{out} = number of the results removed before calculationN_{suc} = number of successful resultsS_{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability								
							AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel} [%]	
(220) Haemoglobin A_{1c}	[mmol/mol]				134							134	122	91	
Sample A		73,4	4	5,4	134		CVP	73,4	0,84	10%	66	80,8	134	126	94
(14) Bio-Rad		75,9	2,8	3,7	37	0							37		
(25) TOSOH		74,3	2,3	3,1	41	0							41		
(60) Roche		77,4	2,4	3,1	8	0							8		
(150) Arkray		69,5	1,8	2,6	38	0							38		
Other					10	0							10		
								3x 1, 1x 12, 3x 34, 1x 46, 1x 58, 1x 162							
Sample B		32,3	1,9	5,8	134		CVP	32,3	0,39	10%	29	35,6	134	124	93
(14) Bio-Rad		32,4	1,6	5	37	0							37		
(25) TOSOH		33,3	1,3	3,9	41	0							41		
(60) Roche		32,9	2,1	6,3	8	0							8		
(150) Arkray		31	1	3,3	38	0							38		
Other					10	0							10		
								3x 1, 1x 12, 3x 34, 1x 46, 1x 58, 1x 162							